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ABSTRACT
Objective Endoscopic mucosal biopsies of primary 
gastric cancers (GCs) are used to guide diagnosis, 
biomarker testing and treatment. Spatial intratumoural 
heterogeneity (ITH) may influence biopsy- derived 
information. We aimed to study ITH of primary GCs and 
matched lymph node metastasis (LNmet).
Design GC resection samples were annotated to 
identify primary tumour superficial (PTsup), primary tumour 
deep (PTdeep) and LNmet subregions. For each subregion, 
we determined (1) transcriptomic profiles (NanoString 
’PanCancer Progression Panel’, 770 genes); (2) next- 
generation sequencing (NGS, 225 gastrointestinal 
cancer- related genes); (3) DNA copy number profiles by 
multiplex ligation- dependent probe amplification (MLPA, 
16 genes); and (4) histomorphological phenotypes.
Results NanoString profiling of 64 GCs revealed 
no differences between PTsup1 and PTsup2, while 43% 
of genes were differentially expressed between PTsup 
versus PTdeep and 38% in PTsup versus LNmet. Only 16% 
of genes were differently expressed between PTdeep 
and LNmet. Several genes with therapeutic potential (eg 
IGF1, PIK3CD and TGFB1) were overexpressed in LNmet 
and PTdeep compared with PTsup. NGS data revealed 
orthogonal support of NanoString results with 40% 
mutations present in PTdeep and/or LNmet, but not in PTsup. 
Conversely, only 6% of mutations were present in PTsup 
and were absent in PTdeep and LNmet. MLPA demonstrated 
significant ITH between subregions and progressive 
genomic changes from PTsup to PTdeep/LNmet.
Conclusion In GC, regional lymph node metastases 
are likely to originate from deeper subregions of 
the primary tumour. Future clinical trials of novel 
targeted therapies must consider assessment of deeper 
subregions of the primary tumour and/or metastases as 
several therapeutically relevant genes are only mutated, 
overexpressed or amplified in these regions.
INTRODUCTION
Gastric cancer (GC) is a leading cause of mortality 
and morbidity worldwide.1 Targeting of specific 
cancer- associated driver genes has improved 
outcomes in patients with lung, breast or colorectal 
cancer.2–6 However, similar approaches have 
only proved modestly successful in patients with 
GC. Tumour heterogeneity has been proposed 
as a major hurdle to developing novel therapeu-
tics for patients with GC.7 While intertumoural 
Significance of this study
What is already known on this subject?
 ► Tumour heterogeneity of gastric cancer (GC) 
has been proposed as a major hurdle to 
developing novel targeted therapeutics.
 ► Genomic differences between primary and 
metastatic tumour sites have been reported as 
a potential barrier for precision oncology.
 ► Several previous studies have confirmed 
intertumoural heterogeneity in GC.
What are the new findings?
 ► We studied intratumoural spatial heterogeneity 
in GC by annotating superficial and deep 
subregions of the primary tumour as well as 
tumour in matched lymph node metastasis 
(LNmet) from GC resection specimens.
 ► By performing phenotypical, genomic and 
transcriptomic profiling, we found superficial 
subregion profiles to be significantly different 
compared with matched deep subregions and 
LNmet. At the same time, profiles of matched 
deep subregions and metastatic lymph nodes 
exhibited greater similarity.
 ► Several therapeutically targetable genes were 
amplified, mutated and/or overexpressed in 
the deep subregions and/or LNmet but not in the 
superficial subregions.
How might it impact on clinical practice in the 
foreseeable future?
 ► Multiple superficial endoscopic biopsies 
are unlikely to reflect the whole breadth of 
intratumoural heterogeneity in GC.
 ► Future clinical trials of novel targeted therapies 
must consider assessment of the deeper 
subregions of the primary tumour and/or 
metastases.
 ► New understanding of the biology of metastatic 
dissemination of GC will allow advances in 
drug discovery and treatment.
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heterogeneity (ie, between patients) has been described in GC 
in some detail,8 9 intratumoural heterogeneity (ITH) (ie, within 
the same patient) is less well studied. Genomic differences 
between primary and metastatic GC sites have been recently 
reported as a potential barrier for precision oncology.10 Clini-
cally, cancer diagnosis and treatment choices are usually made 
by evaluation of endoscopic biopsies taken from the luminal 
aspects of the primary tumour (‘superficial mucosa’). In 
contrast, material from deeper tumour regions or metastatic 
sites such as regional lymph node metastasis (LNmet) or distant 
metastasis is often not easily accessible and therefore usually 
not investigated at the time of diagnosis.
In this study, we hypothesised that luminal and deep subre-
gions of primary GCs exhibit systematic differences in cancer- 
related genes and pathways, and that these differences might also 
relate to the molecular profiles of patient- matched lymph node 
metastases. To investigate this, we adopted a multiassay strategy 
to profile various regions from primary GCs and matched lymph 




This cohort included patients diagnosed with gastric adeno-
carcinoma who underwent potentially curative surgery at the 
Department of Surgery, Leeds Teaching Hospital NHS Trust 
(Leeds, UK) between 1985 and 2003. Patients were included in 
the study if the adenocarcinoma invaded at least the muscularis 
propria, and lymph node metastases with sufficient tumour for 
RNA and DNA extraction were present. None of the patients 
underwent perioperative chemotherapy. Clinical and patholog-
ical data were retrieved from histopathology reports, electronic 
patient hospital records and the Northern and Yorkshire Cancer 
Registry.
Representative Haematoxylin/Eosin (H&E) stained sections 
from the resection specimen were scanned using an Aperio slide 
scanner (Aperio XT; Aperio Technologies, Vista, California, 
USA), reviewed, and multiple subregions were manually delin-
eated in the primary tumour: two adjacent luminal subregions 
(primary tumour superficial (PTsup1) and PTsup2) extending up to 
2 mm deep into the mucosa/superficial submucosa approximately 
equivalent to the depth that is reached by endoscopic biopsy, 
one deep tumour subregion (primary tumour deep (PTdeep)) 
extending from 2 mm depth to the deepest point of tumour infil-
tration in the wall. The median size of the individual superficial 
region was 35 mm2, which is equivalent to the amount of tissue 
that can be obtained from approximately eight endoscopic biop-
sies. In addition, tumour was outlined in the lymph node with 
the largest contiguous metastatic tumour area (LNmet) (figure 1).
Histomorphological phenotype classification
The histological phenotype of all cases was classified by a pathol-
ogist without knowledge of associated clinicopathological infor-
mation or results from RNA/DNA investigations. Every subregion 
(PTsup1, PTsup2, PTdeep and LNmet) was assessed for the presence of 
three main histological phenotypes: poorly cohesive, non- poorly 
cohesive and mucinous phenotypes. For poorly cohesive cancers, 
the presence of signet- ring cells was recorded according to the 
recently published consensus as <10%, 10%–90% or ≥90% 
signet- ring cells.11 Signet- ring cells were defined as cells with an 
eccentric nucleus and optically clear cytoplasmic mucin on the 
H&E- stained slides.
Quantification of tumour and stroma content per subregion
The tumour and stroma content was quantified in all cases for 
each primary tumour subregion and LNmet separately using the 
same tissue section and the same outlines as used for DNA and 
RNA extractions. The stereology tool in the MIM software 
(HeteroGenius, Leeds, UK) was used to take a random system-
atic sample of 300 points per subregion as described previously.12 
The tissue category (tumour epithelium vs stroma (anything in 
between epithelial tumour cells) vs non- informative (normal 
epithelium, artefacts and non- interpretable tissue)) was deter-
mined for every point. The tumour:stroma ratio per subregion 
was calculated by dividing the number of tumour points by the 
number of stroma points.
DNA and RNA extraction
DNA and RNA were extracted from the subregions separately. 
DNA was extracted using the QIAmp DNA Micro Kit (Qiagen, 
Hilden, Germany) as previously described.13 DNA concentration 
was measured by ND- 100 Spectrophotometer (Labtech Interna-
tional) and samples were diluted using Tris- EDTA buffer. RNA 
was extracted using the Qiagen RNeasy Kit (Qiagen) according 
to the instructions of the manufacturer.
NanoString analysis
The ‘PanCancer Progression Panel’ NanoString nCounter 
Reporter CodeSet (Nanostring Technologies, USA) was used for 
this study. This panel includes 770 genes covering a range of 
cancer- related pathways, including angiogenesis, extracellular 
matrix (ECM) remodelling, epithelial- to- mesenchymal transition 
and metastasis (online supplemental table S1). Pathway annota-
tions were based on NanoString panel designation, which was 
curated from publicly available data sources.14–16 Raw counts 
were normalised using the geometric mean of the internal posi-
tive control probes included in the CodeSet using the vendor- 
provided nCounter software (nSolver). ITH was quantified by 
calculating the arithmetic mean of the standard deviation (SD) of 
gene expression between subregions per gene for each tumour. 
GCs with mean SD>50th centile were classified as ITHhigh, all 
others were classified as ITHlow.
Quantitative reverse transcriptase- PCR (qRT- PCR) valida-
tion of NanoString transcriptomic findings was performed for 
selected genes (TGFB, CLDN4, CDH1, FGF18 and CEACAM6) 
using RNA extracted from the different tumour subregions. One- 
step qRT- PCR was performed using the KAPA SYBR FAST One 
step universal kit (Sigma, Thermofisher USA) and gene- specific 
primers (sequences shown in online supplemental table S2). 
Triplicate runs were performed from each subregion. To calcu-
late fold changes of gene expression between subregions, the 
delta–delta cycle threshold (ΔΔCT) method was used.17 GAPDH 
was used as endogenous control for normalisation. Comparisons 
for ΔΔCT were made using LNmet as reference, and relative quan-
tification was calculated as 2−ΔΔCT. For each tumour, pairwise 
comparisons between PTsup, PTdeep and LNmet were performed 
and the direction of fold change was compared with the NanoS-
tring results (eg, the value of PTsup greater than PTdeep in both 
qRT- PCR and NanoString for a particular GC).
Next-generation sequencing (NGS) analysis
DNA was sheared to 200 base pairs using a sonicator and 
cleaned- up with 1.4X Agencourt AMPure XP beads (Beckman 
Coulter, A63881). Libraries were generated using the KAPA 
Hyper Prep Kit (Roche, KK8504). Hybridisation capture was 
done using an IDT xGen Custom Panel of 225 genes (online 
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supplemental table S3) and reagents as per manufacturer’s 
instruction (xGen Hybridization and Wash Kit, IDT 1080577). 
Sequencing was performed on an Illumina NextSeq 550 System 
Mid- Output Kit (2×150 paired).
Sequence reads were processed using the bcbio- nextgen pipe-
line V.1.1.1a0 with default settings, including adapter trimming, 
quality filtering and read mapping on the reference genome hg38 















Figure 1 Pathology selection of tumour subregions. Blocks with highest tumour content per area were selected from the resection specimen 
and subregions were manually delineated in the primary tumour by a pathologist: two adjacent luminal subregions (PTsup1 and PTsup2) extending 
approximately 2 mm deep into the mucosa/superficial submucosa equivalent to the depth that is reached by endoscopic biopsy, one deep tumour 
subregion (PTdeep) extending from 2 mm depth to the deepest point of tumour infiltration in the wall. The median size of the individual superficial 
region was 35 mm2, which is equivalent to the amount of tissue that can be obtained from approximately eight endoscopic biopsies. In addition, 
tumour was outlined in the lymph node with the largest contiguous metastatic tumour area (LNmet). Cytokeratin- stained images are provided in this 
figure for illustrative purposes only to facilitate visualisation of tumour cells (3,3'-diaminobenzidine (DAB) brown). LNmet, lymph node metastasis; 
PTdeep, primary tumour deep; PTsup, primary tumour superficial.
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GATK MarkDuplicates. Quality statistics and on- target analysis 
of coverage were performed using samtools V.1.9 and bedtools 
V.2.27.1. Variants were called using VarDict, and somatic vari-
ants per patient were annotated using Ensembl VEP V.23. Only 
variants with moderate or high impact, with maximum popu-
lation variant frequency of >0.00001 and number of alternate 
supporting reads of >10 were considered for further analyses.
Multiplex ligation-dependent probe amplification (MLPA) 
assay
Details of the MLPA assay, including probemix development, 
sensitivity against single- nucleotide polymorphisms and fluo-
rescent in situ hybridisation using GC cell lines, have been 
previously described.18 The MLPA probemix P458- B1 (MRC- 
Holland, NL) included the genes EGFR, ERBB2, FGFR2, MET, 
TOP2A, KRAS, MYC, PTP4A3, PIK3CA, KLF5, CCNE1, GATA6, 
FGFR1, GATA4, CDK6 and CCND1.
The MLPA analysis methodology has been previously 
described.19 20 In short, analyses were performed using the 
MLPA intermethod,19 20 whereby samples were normalised per 
batch using samples processed in each batch. Quality control 
ensured that samples with low overall intensity, with a large 
difference in intensity between short probes and long probes, 
with low intensity of denaturation controls, or high within- gene 
variation, defined as the average of the SD of log- transformed 
values were excluded.
Final values were calculated by averaging the peak height of 
each probe and then averaging the results of replicates. Copy 
number thresholds were set according to previously published 
studies18 21 as follows: a gene copy number ratio of less than 0.80 
was categorised as ‘loss’, between >0.80 and 1.30 as ‘normal’, 
between >1.30 and 2.0 as ‘low amplification’, between >2.0 and 
5.0 as ‘high amplification’ and >5.0 as ‘very high amplifica-
tion’. Pairwise comparisons were made within each GC between 
subregions. If the copy number aberrations were the same in the 
subregions, concordance was established (eg, normal for PTsup 
and normal for PTdeep for a particular gene in a GC were classi-
fied as concordant), while discordance was defined as a different 
value for the comparison (eg, ‘loss’ or ‘amplification’ for LNmet 
and normal for PTsup for a particular gene in a GC was classified 
as discordant).
Statistical analyses
Categorical data such as sex, pT (depth of invasion) and pN 
(lymph node status) were compared using Fisher’s exact test. 
Comparison of NanoString RNA expression values between 
LNmet, PTsup and PTdeep was performed using non‐parametric 
paired Wilcoxon signed- rank test with false discovery rate 
(FDR) corrections for multiple hypothesis testing. An adjusted 
p value of <0.05 was considered statistically significant. Unsu-
pervised hierarchical clustering of samples was done using 
principal component analysis and the ggbiplot package. After 
calculating the principal components of the explained variance 
when centred and scaled, a mean centre point for each cluster 
was calculated for generation of ellipses. Kaplan- Meier plots 
and log- rank statistics were used for survival analysis. All statis-
tical analyses were performed using R V.3.6.1 (R Foundation for 
Statistical Computing, Vienna, Austria).
RESULTS
For this study, up to 64 primary GCs and matched regional lymph 
node metastases from patients with locally advanced resectable 
GC were included per assay. Each patient had several tumour 
subregions analysed: primary tumour from the luminal (super-
ficial) surface, which was subdivided into two parts (PTsup1 and 
PTsup2); primary tumour from deep regions (PTdeep); and tumour 
regions in regional lymph nodes (LNmet). Based on quality of 
DNA/RNA extracted from each sample, different numbers of 
samples were available for the various assays (online supple-
mental table S4). All 64 (100%) GCs had clinical and histological 
phenotyping data available. The median age was 71 years (range: 
39–91 years), and 73% were male. Most GCs were of intestinal 
type (92%); six (9%) GCs were Epstein- Barr virus positive; and 
five (8%) GCs were mismatch repair (MMR) protein deficient 
(online supplemental table S5). The estimated median overall 
survival was 1.02 years (95% CI 0.80 to 1.58).
Differential expression of genes between spatial subregions 
in primary tumor and matched metastatic lymph node
After quality control, NanoString data were available from PTsup1 
(63 (98%)), PTsup2 (54 (84%)), PTdeep (57 (89%)) and LNmet (51 
(80%)) GCs, respectively (online supplemental tables S4 and S6). 
Transcriptomic profiles consisting of 770 genes were compared 
for differential expression between subregions. Between samples 
that had matched LNmet and samples that did not, we did not 
observe any significant clinicopathological differences at the 
transcriptomic level (online supplemental figure S1). When 
PTsup1 and PTsup2 were compared within the same patient, none of 
the 770 genes was significantly differently expressed after false 
discovery rate (FDR) correction for multiplicity (online supple-
mental figure S2). Furthermore, there was a strong correlation 
of the transcriptomic profiles between the two adjacent luminal 
GC subregions (Spearman’s R=0.95, p<0.0001) (online supple-
mental figure S3). For further analyses of NanoString data, PTsup1 
values were designated PTsup and compared with PTdeep subregion 
and LNmet samples.
Differential gene expression analysis between PTdeep and 
PTsup subregions identified 331 (43%) genes which were signifi-
cantly different between the two subregions (figure 2A). Genes 
mapping to the ‘ECM’ and ‘tumour growth’ pathways were the 
genes most differentially expressed between PTsup and PTdeep 
subregions (online supplemental table S7).
Differential gene expression analysis between PTsup and LNmet 
subregions identified 291 (38%) genes as significantly different 
between the two subregions (figure 2B and online supplemental 
table S8). PTsup had 186 (24%) genes overexpressed compared 
with LNmet, while LNmet had 105 (14%) genes overexpressed 
compared with PTsup (table 1). Genes mapping to the ‘angiogen-
esis’ and ‘tumour invasion’ pathways were the most commonly 
differentially expressed genes between PTsup and LNmet. Approxi-
mately 10% of genes were found to overlap between the compar-
ison of PTsup versus PTdeep and PTsup versus LNmet (81 genes were 
overexpressed in PTsup compared with PTdeep and LNmet, while 69 
genes were overexpressed in PTdeep and LNmet compared with 
PTsup). Several of these genes were potential therapeutic targets, 
such as APOE, ERCC3, HDAC3, IGF1, PIK3CD, PRF1, TGFB1 
and VEGFC (higher in PTdeep and LNmet) and CDH1, CEACAM5, 
CEACAM6, MAPK1, MAPK3, MUC1 and WNT5A (higher in 
PTsup). Quantitative RT- PCR was performed on selected genes 
and validated the NanoString gene expression findings (online 
supplemental figure S4).
Differential gene expression analysis between PTdeep and LNmet 
subregions identified 127 (16%) genes as significantly different 
between the two subregions (figure 2C and online supplemental 
table S9). Of these, 117 (15%) genes were overexpressed in 
PTdeep compared with 10 (1%) overexpressed genes in LNmet 
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(table 1). Similar to the analysis comparing PTsup and LNmet, most 
of the differentially expressed genes belonged to the angiogenesis 
and tumour invasion pathways. Genes such as FGF2, WNT5A, 
FGFR1, FAP, HIF1A, PDGFRB and CDH11 were overexpressed 
in PTdeep. The lower number of genes with differential expres-
sion between PTdeep and LNmet suggests that the RNA expression 
profile of the tumour in LNmet is likely more similar to the deep 
subregion of the primary tumour than to superficial subregions.
We classified samples into ITHhigh and ITHlow based on the 
mean SD of gene expression between subregions. We found no 
significant relationship between ITH and clinicopathological 
characteristics (online supplemental tables S10 and S11 and 
online supplemental figure S5). We found that genes previously 
used to classify intertumoural heterogeneity of GC such as KRAS, 
TP53, SMAD4 and WARS showed low ITH (below the 10th 
centile).8 9 22 Certain genes with therapeutic and clinical rele-
vance such as CEACAM6, CEACAM5 and EGF had the highest 
ITH (above the 90th centile) (online supplemental table S12).23
In this study, we selected tissue blocks for analysis based on 
highest tumour content. Subregions were annotated for DNA 
and RNA extraction and morphometric and phenotypic assess-
ment by a senior GI pathologist (figure 1). To address the possi-
bility that differences in ‘contaminating’ normal tissue might 
confound our results, we morphometrically quantified the 
tumour:stroma ratio per subregion (online supplemental table 
S13) and compared it between subregions in the same patient. 
The median tumour:stroma ratio was 0.45 (IQR 0.32–0.60). 
There was no difference in the tumour:stroma ratio between 
PTsup and LNmet (median 0.51 (PTsup) vs 0.47 (LNmet), p=0.49), 
whereas the tumour:stroma ratio between PTsup and PTdeep 
was significantly different (median 0.35 (PTdeep), p<0.001). 
However, it is important to note that we observed a significant 
overlap in highly expressed genes common to both PTdeep and 
LNmet regions compared with PTsup subregions, which is more 
consistent with cancer cell- related expression. These included 
several well- known oncogenes and other cancer- related genes 
Figure 2 Volcano plots comparing differential gene expression between subregions. (A) Volcano plot of 770 genes from the NanoString PanCancer 
progression panel comparing differential gene expression between PTdeep and PTsup. The x- axis is the log2 fold change of gene expression between 
PTsup and PTdeep. The y- axis is the −log10 adjusted p value results (false discovery rate correction). Genes of interest have been annotated within the 
plot. Grey dots are genes which are similarly expressed in PTdeep and PTsup. Green dots are genes which are statistically significant and belong to the 
‘tumour growth’ pathway. Orange dots are genes which are statistically significant and belong to the ‘ECM remodelling’ pathway. Black dots are 
genes which are statistically significant and belong to other pathways. In general, genes which are at the extreme ends of the volcano are highly 
differentially expressed in that particular subregion compared with the other and are of greatest clinical interest. (B) Volcano plot of genes comparing 
LNmet and PTsup. Red dots are genes which are statistically significant and belong to the ‘angiogenesis’ pathway. Blue dots are genes which are 
statistically significant and belong to the ‘tumour invasion’ pathway. Black dots are genes which are statistically significant and belong to other 
pathways. Grey dots are genes which are similarly expressed in LNmet and PTsup. (C) Volcano plot of genes compared between LNmet and PTdeep. Red 
dots are genes which are statistically significant and belong to the angiogenesis pathway. Blue dots are genes which are statistically significant and 
belong to the tumour invasion pathway. Black dots are genes which are statistically significant and belong to other pathways. Grey dots are genes 
which are similarly expressed in LNmet and PTdeep. ECM, extracellular matrix; LNmet, lymph node metastasis; PTdeep, primary tumour deep; PTsup, primary 
tumour superficial.
Table 1 Number of genes in the NanoString panel with significant differences in matched paired analyses of tumour subregions
LNmet versus PTsup versus PTdeep GCs compared (n)
Genes sig different,
n (% of 770)
A>B
n (% of 770)
A>1.5×B
n (% of 770)
B>A
n (% of 770)
B>1.5×A
n (% of 770)
PTsup1 versus PTsup2 54 0 0 0 0 0
PTdeep versus PTsup 57 331 (43) 231 (30) 45 (6) 100 (13) 11 (1)
LNmet versus PTsup 50 291 (38) 105 (14) 35 (5) 186 (24) 54 (7)
LNmet versus PTdeep 46 127 (16) 10 (1) 5 (<1) 117 (15) 75 (10)
A is the first subregion in the corresponding row of the first column (LNmet vs PTsup vs PTdeep).
B is the second subregion in the corresponding row of the first column (LNmet vs PTsup vs PTdeep).
For example, in the first row, A=PTsup1 and B=PTsup2.
GC, gastric cancer; LNmet, lymph node metastasis; PTdeep, primary tumour deep; PTsup, primary tumour superficial; sig, significant.
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commonly expressed in both PTdeep and LNmet regions compared 
with PTsup (eg, TGFB1, PIK3CD, IGF1 and VEGFC). These find-
ings suggest that differences in tumour content proportions are 
unlikely to have played a major role in the transcriptomic differ-
ences between subregions.
DNA spatial heterogeneity in gastric cancer
An NGS panel of 225 genes commonly altered in GI cancers 
was analysed in eight GCs (three subregions per sample: PTsup, 
PTdeep and LNmet). Mutations were detected in one to six genes 
per subregion, except for GC case TH316, where 33–44 
mutations per subregion were detected (note that TH316 is 
an MMR- deficient tumour). Of the 225 genes included in the 
panel, mutations were detected in 53 (24%) genes. TP53 muta-
tions were the most commonly detected mutations and present 
in 50% of GCs. Of these 53 genes, 21 (40%) genes had muta-
tions in PTdeep and/or LNmet, but not in PTsup. Conversely, only 
three (6%) genes had mutations in PTsup but not in PTdeep and 
LNmet (figure 3). For 44 genes, at least one GC had mutations 
detected in all three subregions. In these, allele frequency values 
were compared between subregions. In 33 (75%) genes, the 
allele frequency of the specified gene in the LNmet subregion was 
higher than PTsup (online supplemental table S14). These findings 
from the NGS mutation analysis provide orthogonal support of 
the NanoString data for spatial ITH between subregions, partic-
ularly between PTsup compared with PTdeep and/or LNmet.
Apart from studying ITH of single- base DNA mutations, we 
also studied gene copy number variation by analysing MLPA 
subregion data. Of the 64 samples used for the NanoString 
analysis, 41 (64%) had sufficient DNA quantity and quality to 
perform the MLPA analysis. There were no significant clinical 
differences between cases with MLPA data and those without 
(online supplemental tables S4 and S5). Furthermore, to reduce 
‘missing- data bias’, we included additional 20 GCs for MLPA 
profiling to have a total of 61 GC for MLPA analysis (additional 
sample clinical data available in online supplemental table S15). 
Ninety- one per cent of the 16 genes across 61 samples per three 
subregions were categorised as ‘normal’ copy number. The 
highest frequency of gene copy number aberrations was found 
in CCNE1 (15%), GATA4 (16%) and MYC (15%), range of gene 
copy number aberrations 2%–16% (online supplemental table 
S16). Pairwise comparisons of gene copy number values were 
made between subregions to study ITH. Out of 976 comparisons 
(61 samples×16 genes) for each subregion pairing, the highest 
discordance was seen between PTsup and LNmet (PTsup vs LNmet 112 
(11%) discordant comparisons); followed by PTdeep versus LNmet 
(93 (10%) discordant comparisons) and finally PTsup versus PTdeep 
(75 (8%) discordant comparisons), consistent with progressive 
genomic changes from PTsup to LNmet.
Phenotypical spatial heterogeneity in gastric cancer
In total, 228 subregions from 64 GCs had phenotypical 
subtyping performed. Sixty- one (27%) subregions were classi-
fied as poorly cohesive, 158 (69%) as non- poorly cohesive and 
9 (4%) as mucinous. Of the 61 poorly cohesive subregions, 49 
(80%) contained signet- ring cells. When intratumoural subre-
gions were compared, only eight GCs (13%) demonstrated 
different phenotypical classifications between subregions (online 
supplemental table S17). There was little correlation between 
phenotypic and transcriptomic ITH. Subregions with the same 
phenotype showed transcriptomic differences, while in some 
cases, subregions with different phenotypes appeared to have 
similar transcriptomic profiles. We selected one GC to illustrate 
this phenomenon (figure 4). In the majority of the cases which 
had no phenotypical ITH (n=56, 88%), there was a variable 
degree of transcriptomic ITH. We selected two GCs with the no 
phenotypical ITH to illustrate one GC with low transcriptomic 
Figure 3 NGS analysis of spatial heterogeneity in GC. Heatmap of DNA mutations detected by performing NGS of 225 genes per subregion on eight 
GCs. GCs are represented into columns, with subregions forming subcolumns within each column in the order of PTsup, PTdeep and LNmet. Genes where 
mutations were detected in at least one subregion of one GC are represented in rows. Genes which had mutations called in all three subregions (ie, 
no ITH) were coded green; genes which had mutational calls in PTsup but not PTdeep or LNmet were coded in red; those with mutational calls in either 
PTdeep and/or LNmet but not PTsup were coded in blue; and PTsup and PTdeep but not LNmet or PTsup and LNmet but not PTdeep were coded in yellow. Bar graph 
shows prevalence of mutations detected in PTdeep and/or LNmet (blue) but not PTsup is significantly higher than any other combination of spatial ITH. 
ITH, intratumoural heterogeneity; LNmet, lymph node metastasis; NGS, next- generation sequencing; PTdeep, primary tumour deep; PTsup, primary tumour 
superficial.
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ITH (ITHlow) and one GC with extensive transcriptomic ITH 
(ITHhigh) (figure 5).
DISCUSSION
Gastric cancer has long been recognised as a heterogenous group 
of adenocarcinomas. Classifying GC into more homogenous 
subtypes might allow the development of subtype- specific treat-
ments under the overarching umbrella of ‘precision oncology’. 
To increase ‘coverage’ of potential intratumour heterogeneity, 
one could consider increasing the number of endoscopic biop-
sies beyond the current standard of six to eight.24 25 It has been 
shown that HER2- positive GC cells are more frequent in the 
luminal tumour surface compared with deeper layers and that 
at least five tumour containing endoscopic biopsies are needed 
for reliable HER2 testing.26 Similar spatial heterogeneity has 
been demonstrated when measuring FGFR2 copy number in 
GC.27 However, whether a larger number of endoscopic biop-
sies would also be sufficient to address ITH for other DNA or 
RNA- based biomarkers, as well as for the histological pheno-
type, is currently unknown. A recent study suggested that circu-
lating cell- free DNA measured in the blood detects mutations 
not identified in multiple endoscopic biopsies in GC.28 Spatial 
annotation of tumours and biopsy samples has only infrequently 
been considered in clinical biomarker tests or research analyses 
in the past.
In this study, we annotated surgical resection samples and 
demarcated multiple superficial (luminal/mucosal) and deep 
regions of primary GC, as well as tumour in matched lymph 
node metastases, and analysed these subregions individually 
using multiple platforms such as RNA expression analyses, NGS 
mutation analysis, DNA copy number and histomorphology. 
Other studies have demonstrated a relationship between molec-
ular characteristics and histological phenotype in GC but did not 
include a spatial perspective.9 19 In oesophageal adenocarcinoma, 
whole- genome sequencing of matched primary tumour, LNmet 
and distant metastatic sites suggests subclonal mutations found 
in distant metastases were found in spatially distinct areas of 
the primary tumour.29 While differentiation between superficial 
and deep aspects of the tumour was not performed, this study, 
as well as another similar study performed in colorectal cancer, 
confirms a distinct model of metastasis with diverse trajectories 
for lymph node and distant organ dissemination.30
Our results yielded several findings of potential clinical and 
biological relevance. First, we observed minimal differences in 
gene expression between superficial subregions from the same 
GC. This suggests that increasing the number of endoscopic 
Figure 4 Phenotypical and transcriptomic heterogeneity in gastric cancer. TH657 is an example of a tumour with phenotypical heterogeneity. (A–C) 
H&E images of the tumour subregions. (A) Superficial subregion (PTsup) which demonstrates a non- poorly cohesive subtype, with no signet- rings. (B) 
Deep subregion (PTdeep), which is poorly cohesive and has 10%–90% signet- rings. (C) Metastatic lymph node (LNmet) which has <10% signet- rings and 
is poorly cohesive. (D) Heatmap of NanoString expression profile of TH657 by various spatial subregion. NanoString gene expression is represented in 
columns, scaled. Blue to red denotes gene expression, with blue implying low gene expression and red implying high gene expression. There is little 
correlation between phenotypical and transcriptomic heterogeneity. For example, PTsup1 and PTsup2 are phenotypically different (PTsup1 is non- poorly 
cohesive, while PTsup2 is poorly cohesive) but have similar transcriptomic profiles. However, PTsup2 and PTdeep have the same phenotype, but significantly 
different transcript profiles. LN, lymph node; LNmet, lymph node metastasis; PT, primary tumour; PTdeep, primary tumour deep; PTsup, primary tumour 
superficial.
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tumour biopsies may not be sufficient to fully characterise intra-
tumour heterogeneity. Next, we observed significant differences 
in gene expression, mutations and amplification between super-
ficial subregions, deep subregions and LNmet. Several genes are 
differentially upregulated in the deeper aspect of the tumour 
and LNmet. Interestingly, fewer differences were detected in gene 
overexpression between the deep subregion of the tumour and 
the LNmet. This observation is consistent with a model where 
tumour cells in the regional LNmet are more likely to originate 
from the deep tumour subregion than from the mucosal (super-
ficial) subregion. Based on these findings, biomarker analyses 
performed on superficial biopsies alone may miss important 
genomic alterations that occur in the deep subregions and/or 
metastatic sites which drive tumour oncogenesis and may be 
potentially targetable. Our results are consistent with the princi-
ples of clonal evolution of GI tumours from superficial to deep 
to metastases which were described over three decades ago by 
Fearon and Vogelstein.31 Yet, most of these previous studies 
were conducted by analysing and comparing tumours with 
different depths of invasion. The present study is one of the 
first to describe this phenomenon within the same tumour in 
GC. Importantly, from the differential gene expression analysis, 
genes mapping to angiogenesis and tumour invasion pathways 
were enriched in the PTdeep and LNmet subregions, providing 
a plausible biological rationale for our findings. In a previous 
small study (n=15 GCs) of matched primary tumour and lymph 
node metastases, whole- exome sequencing data were analysed, 
and mutational abundance was compared. This study suggested 
that lymph node metastases arise from specific subclonal regions 
of the primary tumour.32 These findings can be corroborated 
with our deeper analyses by spatial subregions.
Matched primary tumour, lymph node and distant metas-
tasis studies of other tumour types (eg, colorectal and lung 
cancer) report similar findings.33–37 In a study of melanoma 
lymph node biopsies, spatial transcriptomics revealed that the 
lymph node region closest to the primary tumour displayed 
expression patterns that reflected the tumour microenviron-
ment of the primary tumour.38 ITH has also been assessed 
by other groups in gastro- oesophageal adenocarcinoma.10 39 
However, the principal difference between those studies and 
Figure 5 Phenotype and NanoString gene expression of select GC. (A) Heatmap of NanoString gene expression of TH112 (ITHlow) and TH295 
(ITHhigh). (B–D) are H&E images of TH112 subregions (B=PTsup, C=PTdeep and D=LNmet). (E–G) H&E images of TH295 subregions (E=PTsup, F=PTdeep and 
G=LNmet). Phenotypically, both samples do not have significant heterogeneity between subregions—all subregions for both TH112 and TH295 were 
classified as non- poorly cohesive, no signet- ring cells and no mucin. In the heatmap (A), TH112 (top four rows) is an example of a tumour with low 
transcriptomic ITH in this cohort, while TH295 (bottom four rows) is an example of high transcriptomic ITH. The heatmap demonstrates obvious 
heterogeneity in gene expression between TH295 PTdeep and the rest of the subregions TH295 LNmet, PTsup1 and PTsup2. In contrast, for TH112, there are 
minimal differences in gene expression between the LNmet, PTsup1, PTsup2 and PTdeep. ITH, intratumoural heterogeneity; LNmet, lymph node metastasis; 
PTdeep, primary tumour deep; PTsup, primary tumour superficial
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ours is spatial mapping performed prior to analysis, demar-
cating superficial and deep aspects of the tumour with subse-
quent molecular analysis defined by these spatial regions. Our 
NGS analysis of ITH in GC included one MMR- deficient 
tumour. To the best of our knowledge, this is the first descrip-
tion of mutational spatial heterogeneity in an MMR- deficient 
GC. Given the therapeutic implications of MMR deficiency 
and treatment with immune checkpoint blockade,40 41 studies 
are emerging on ITH as a potential mechanism of resistance to 
this form of therapy.42
Limitations of the present study include the time period 
during which these samples were accrued from and the anal-
ysis being limited only to primary tumours and LNmet and did 
not include distant metastatic sites. Our samples were collected 
from an era before perioperative or adjuvant chemotherapy was 
administered routinely for GC, and thus, a potential relationship 
of ITH with chemotherapy cannot be investigated in the current 
study. However, one might also consider the absence of chemo-
therapy an advantage as expression profiles, genomic profiles 
and phenotypical appearances are not altered by preoperative 
treatment. A retrospective cohort study of spatial heterogeneity 
in GC has demonstrated poorer survival for those with higher 
ITH.43 However, from our study, it is unclear if tumour biology 
driven by ITH can be altered with chemotherapy or if this is a 
factor that drives resistance to systemic therapy, which must be 
considered in future studies. As the inclusion criteria for the study 
required tumours which were metastatic to the lymph node and 
that had undergone surgical resection, earlier stage, lymph node- 
negative tumours and advanced, surgically inoperable tumours 
were not included. Thus, we do not know whether the observed 
ITH is specific to tumours with lymph node metastases or can 
also be observed in primary GC without lymph node metastases. 
Furthermore, while we acknowledge that analyses of more than 
one LNmet from each GC for ITH may produce slightly different 
results on an individual- patient basis, our results are generally 
consistent across the cohort, where randomly selected LNs with 
high tumour cell content were selected for analysis. Moreover, 
a majority of our samples were of intestinal subtype (>90%), 
which rendered our study population relatively homogenous 
with respect to clinicopathological characteristics. While this is 
not necessarily a limitation, it could explain the lack of correla-
tion of ITH with these clinicopathological features and perhaps 
limits the generalisability of our findings to other histological 
subtypes of GC. Discordance between phenotypical and tran-
scriptomic heterogeneity could be due to several reasons, such as 
the phenotype being driven by genes not included in the NanoS-
tring panel or post- translational changes, which would not be 
detected by NanoString.44 45
In conclusion, our study has highlighted clinically significant 
genomic, transcriptomic and phenotypical heterogeneity in GC 
defined by spatial subregions. Several therapeutic targets appear 
to be overexpressed, mutated or amplified only in the deep 
subregions/metastatic lymph nodes. We have elicited potential 
biological mechanisms of tumour metastases from deeper subre-
gions of the tumour to lymph nodes. Endoscopists and pathol-
ogists must consider the potentially limited value of multiple 
superficial endoscopic biopsies for the assessment of presence 
or absence of a biomarker that determines patient treatment and 
consider investigating deeper parts of the primary tumour and/
or metastatic lymph nodes for this purpose. Future studies and 
clinical trials in GC should take this spatial heterogeneity into 
consideration.
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